Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure

The standard of care for stage III colorectal cancer (CRC) is curative resection with adjuvant chemotherapy (ACT). There is a high risk of recurrence particularly for high-risk patients with stage III disease, making close disease monitoring vital. Circulating tumor DNA (ctDNA) is now established as...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucchesi, Nicholas, Ally, Jenna M, Reilley, Matthew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510882/
https://www.ncbi.nlm.nih.gov/pubmed/37714563
http://dx.doi.org/10.1136/jitc-2023-007434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510882/
https://www.ncbi.nlm.nih.gov/pubmed/37714563
http://dx.doi.org/10.1136/jitc-2023-007434

Ejemplares similares